1. Volume 63, Issue 6, Pages 1101-1106 (June 2013)
Indium-111–labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma 
Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders 
European Urology 
Volume 63, Issue 6, Pages (June 2013)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
Posterior 111In-girentuximab image of Patient 14 with a small renal mass in the left kidney. An attempt to biopsy the lesion had failed and the patient underwent 111In-girentuximab immunoSPECT. Besides normal uptake in the right upper abdomen (liver and upper gastrointestinal tract), clear targeting of 111In-girentuximab is seen in lesion (arrow). Histopathologic examination revealed a clear cell renal cell carcinoma with a 12-mm diameter.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

3. Fig. 2
Carbonic anhydrase IX (CAIX) expression in a type 2 papillary tumor. CAIX expression was found in a vital tumor region within a necrotic part of the surgical specimen, suggesting hypoxia-driven expression.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

4. Fig. 3
Images from Patient 29, who had a history of clear cell renal cell carcinoma. After tumor nephrectomy, the patient entered active surveillance. (a) On follow-up computed tomography (CT) scan, a 5-mm lesion in segment 8 of the liver was detected, and biopsy of this lesion was nonconclusive. (b) Clear targeting of the liver lesion on the subsequent 111In-girentuximab immunoSPECT was detected. (c) On a follow-up CT scan 2 mo after immunoSPECT, growth of the lesion was detected and systemic therapy was started.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions